Trade ReShape Lifesciences Inc. - RSLS CFD

Add to favourite

0.40

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.05

Long position overnight fee

-0.026207%

Short position overnight fee

0.003985%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	N/A
Open*	0.4
1-Year Change*	5.26%
Day's Range*	0.39 - 0.47
52 wk Range	0.15-2.22
Average Volume (10 days)	204.12K
Average Volume (3 months)	3.86M
Market Cap	4.21M
P/E Ratio	-100.00K
Shares Outstanding	24.18M
Revenue	12.18M
EPS	-4.40
Dividend (Yield %)	N/A
Beta	-0.18
Next Earnings Date	Mar 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Oct 12, 2023	0.40	-0.01	-2.44%	0.41	0.49	0.38
Sep 29, 2023	0.40	-0.05	-11.11%	0.45	0.49	0.38
Sep 28, 2023	0.41	-0.11	-21.15%	0.52	0.55	0.41
Sep 27, 2023	0.50	-0.01	-1.96%	0.51	0.51	0.50
Sep 26, 2023	0.57	-0.01	-1.72%	0.58	0.60	0.57
Sep 25, 2023	0.59	0.02	3.51%	0.57	0.59	0.55
Sep 22, 2023	0.57	-0.04	-6.56%	0.61	0.62	0.57
Sep 21, 2023	0.58	-0.06	-9.38%	0.64	0.64	0.57
Sep 20, 2023	0.64	0.03	4.92%	0.61	0.65	0.61
Sep 19, 2023	0.63	-0.05	-7.35%	0.68	0.68	0.62
Sep 18, 2023	0.67	-0.06	-8.22%	0.73	0.73	0.65
Sep 15, 2023	0.70	0.00	0.00%	0.70	0.70	0.68
Sep 14, 2023	0.74	-0.05	-6.33%	0.79	0.79	0.72
Sep 13, 2023	0.73	0.00	0.00%	0.73	0.75	0.73
Sep 12, 2023	0.78	-0.07	-8.24%	0.85	0.85	0.76
Sep 11, 2023	0.85	-0.02	-2.30%	0.87	0.87	0.82
Sep 8, 2023	0.81	-0.05	-5.81%	0.86	0.86	0.79
Sep 7, 2023	0.84	-0.05	-5.62%	0.89	0.90	0.84
Sep 6, 2023	0.91	0.03	3.41%	0.88	1.25	0.88
Sep 5, 2023	0.88	0.00	0.00%	0.88	0.89	0.88

ReShape Lifesciences Inc. Events

Time (UTC)	Country	Event
No events scheduled

View all events

Annual
Quarterly

	2021	2020	2019	2018	2017
Total revenue	13.6	1.588	3.281	9.101	9.914
Revenue	13.6	1.588	3.281	9.101	9.914
Cost of Revenue, Total	5.252	1.004	2.95	5.423	4.829
Gross Profit	8.348	0.584	0.331	3.678	5.085
Total Operating Expense	72.162	13.54	26.511	46.066	44.305
Selling/General/Admin. Expenses, Total	31.275	8.776	16.668	29.946	28.829
Research & Development	2.522	2.45	6.893	10.697	10.647
Operating Income	-58.562	-11.952	-23.23	-36.965	-34.391
Interest Income (Expense), Net Non-Operating	-0.664	0.029	-0.385	-0.226	-0.135
Other, Net	-2.813	-0.411	-0.061	-0.189	-0.239
Net Income Before Taxes	-62.039	-12.334	-23.676	-37.38	-34.765
Net Income After Taxes	-61.933	-12.334	-23.676	-37.38	-34.765
Net Income Before Extra. Items	-61.933	-12.334	-23.676	-37.38	-34.765
Net Income	-61.933	-12.334	-23.676	-37.38	-34.765
Income Available to Common Excl. Extra. Items	-61.933	-12.334	-23.676	-37.38	-34.765
Income Available to Common Incl. Extra. Items	-61.933	-12.334	-23.676	-37.38	-34.765
Diluted Net Income	-61.933	-12.334	-23.676	-37.38	-34.765
Diluted Weighted Average Shares	12.3785	2.57943	1.56891	0.63455	0.55723
Diluted EPS Excluding Extraordinary Items	-5.00327	-4.78168	-15.0907	-58.9079	-62.3888
Diluted Normalized EPS	-3.26449	-4.27382	-15.0907	-58.9079	-62.3888
Total Extraordinary Items					0
Dividends per Share - Common Stock Primary Issue					0
Unusual Expense (Income)	33.113	1.31

	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021
Total revenue	2.44	3.142	3.708	3.529	3.221
Revenue	2.44	3.142	3.708	3.529	3.221
Cost of Revenue, Total	1.222	1.366	1.573	1.376	0.937
Gross Profit	1.218	1.776	2.135	2.153	2.284
Total Operating Expense	10.84	38.699	18.692	7.332	7.438
Selling/General/Admin. Expenses, Total	8.87	8.304	15.548	5.752	3.97
Research & Development	0.748	0.277	1.571	0.103	0.571
Unusual Expense (Income)	0	28.752	0	0.101	1.96
Operating Income	-8.4	-35.557	-14.984	-3.803	-4.217
Interest Income (Expense), Net Non-Operating	0.015	-0.03	0.068	-0.071	-0.632
Other, Net	0.013	0	-2.813		0
Net Income Before Taxes	-8.372	-35.587	-17.729	-3.874	-4.849
Net Income After Taxes	-8.215	-35.458	-17.699	-3.902	-4.874
Net Income Before Extra. Items	-8.215	-35.458	-17.699	-3.902	-4.874
Net Income	-8.215	-35.458	-17.699	-3.902	-4.874
Income Available to Common Excl. Extra. Items	-8.215	-35.458	-17.699	-3.902	-4.874
Income Available to Common Incl. Extra. Items	-8.215	-35.458	-17.699	-3.902	-4.874
Diluted Net Income	-8.215	-35.458	-17.699	-3.902	-4.874
Diluted Weighted Average Shares	18.5396	17.874	11.9974	8.22614	3.92799
Diluted EPS Excluding Extraordinary Items	-0.44311	-1.98378	-1.47524	-0.47434	-1.24084
Dividends per Share - Common Stock Primary Issue	0		0	0	0
Diluted Normalized EPS	-0.44311	-0.93819	-1.47524	-0.46636	-0.9165

Annual
Quarterly

	2021	2020	2019	2018	2017
Total Current Assets	30.255	7.835	18.235	28.647	51.755
Cash and Short Term Investments	22.765	3.905	14.055	23.735	44.4
Cash & Equivalents	22.765	3.905	14.055	21.187	21.108
Short Term Investments			0	2.548	23.292
Total Receivables, Net	2.815	3.15	0.285	0.882	4.308
Accounts Receivable - Trade, Net	2.815	0	0.285	0.87	4.223
Total Inventory	3.003	0	1.936	1.58	1.418
Prepaid Expenses	0.736	0.599	1.89	2.329	1.514
Other Current Assets, Total	0.936	0.181	0.069	0.121	0.115
Total Assets	54.258	10.617	20.393	30.386	53.101
Property/Plant/Equipment, Total - Net	1.72	1.478	2.158	1.739	1.346
Property/Plant/Equipment, Total - Gross	2.06	4.082	4.484	3.718	2.761
Accumulated Depreciation, Total	-0.34	-2.604	-2.326	-1.979	-1.415
Total Current Liabilities	7.331	5.046	3.977	17.231	10.011
Payable/Accrued	3.468
Accrued Expenses	2.407	4.431	2.881	5.79	6.267
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0		0.024	9.93	1.958
Other Current Liabilities, Total	1.456	0	0.424	0.352	0.51
Total Liabilities	8.186	5.952	4.544	17.279	17.988
Total Long Term Debt	0	0.43	0	0	7.964
Long Term Debt	0	0.43		0	7.964
Total Equity	46.072	4.665	15.849	13.107	35.113
Preferred Stock - Non Redeemable, Net	0
Common Stock	0.018	0.008	0.008	0.023	0.018
Additional Paid-In Capital	622.906	189.421	188.271	161.838	146.474
Retained Earnings (Accumulated Deficit)	-576.76	-184.764	-172.43	-148.754	-111.374
Other Equity, Total	-0.092			0	-0.005
Total Liabilities & Shareholders’ Equity	54.258	10.617	20.393	30.386	53.101
Total Common Shares Outstanding	17.8319	2.59021	2.57467	0.78377	0.58335
Accounts Payable		0.615	0.648	1.159	1.276
Other Liabilities, Total	0.3	0.476	0.567	0.048	0.013
Other Long Term Assets, Total	1.456	1.304
Intangibles, Net	20.827
Deferred Income Tax	0.555
Total Preferred Shares Outstanding	0.09539

	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021
Total Current Assets	23.627	30.255	37.589	65.605	12.794
Cash and Short Term Investments	15.41	22.765	29.243	40.163	8.972
Cash & Equivalents	15.41	22.765	29.243	40.163	8.972
Total Receivables, Net	2.41	2.815	3.457	3.422	3.15
Prepaid Expenses	0.597	0.736	0.693	1.114	0.495
Other Current Assets, Total	1.212	0.936	0.99	18.012	0.177
Total Assets	47.27	54.258	90.698	120	17.343
Property/Plant/Equipment, Total - Net	1.895	1.72	2.052	2.22	1.312
Property/Plant/Equipment, Total - Gross	0.524	2.06	0.45	0.632	3.982
Accumulated Depreciation, Total		-0.34			-2.67
Other Long Term Assets, Total	1.377	1.456	1.535	1.628	3.237
Total Current Liabilities	8.151	7.331	10.336	60.496	6.863
Accounts Payable				3.095	0.582
Accrued Expenses	2.695	2.899	3.128	53.479	5.851
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases		0	2.971	2.936	0.43
Total Liabilities	8.645	8.186	11.478	61.881	7.245
Total Long Term Debt	0	0	0	0	0
Long Term Debt		0	0	0	0
Other Liabilities, Total	0.127	0.3	0.527	0.77	0.382
Total Equity	38.625	46.072	79.22	58.119	10.098
Common Stock	0.019	0.018	0.018	0.008	0.01
Additional Paid-In Capital	623.652	622.906	620.611	581.823	199.019
Retained Earnings (Accumulated Deficit)	-584.975	-576.76	-541.302	-523.603	-188.931
Total Liabilities & Shareholders’ Equity	47.27	54.258	90.698	120	17.343
Total Common Shares Outstanding	18.5975	17.8319	17.6883	8.16862	3.34052
Accounts Receivable - Trade, Net	2.41	2.815	3.457	3.422
Total Inventory	3.998	3.003	3.206	2.894
Goodwill, Net			21.053	21.623
Intangibles, Net	20.371	20.827	28.469	28.924
Other Current Liabilities, Total	1.858	0.964	1.125	0.986
Deferred Income Tax	0.367	0.555	0.615	0.615
Other Equity, Total	-0.071	-0.092	-0.107	-0.109
Payable/Accrued	3.598	3.468	3.112
Preferred Stock - Non Redeemable, Net	0	0	0
Total Preferred Shares Outstanding	0.09539	0.09539	0.09539

Annual
Quarterly

	2021	2020	2019	2018	2017
Net income/Starting Line	-61.933	-12.334	-23.676	-37.38	-34.765
Cash From Operating Activities	-15.375	-10.409	-22.866	-29.432	-30.624
Cash From Operating Activities	0.232	0.34	0.479	0.581	0.33
Non-Cash Items	47.388	2.985	3.594	4.787	4.907
Cash Taxes Paid	0.102	0	0	0.007	0.002
Cash Interest Paid	0.296	0	0.719	0.642	0.562
Changes in Working Capital	-2.741	-1.4	-3.263	2.58	-1.096
Cash From Investing Activities	1.855	-0.171	2.356	19.517	-21.856
Capital Expenditures	-0.352	-0.171	-0.194	-1.282	-1.043
Other Investing Cash Flow Items, Total	2.207	0	2.55	20.799	-20.813
Cash From Financing Activities	33.299	0.43	13.378	9.994	0.613
Financing Cash Flow Items	-3.234		0	-0.03	0
Issuance (Retirement) of Stock, Net	46.033	0	23.378	10.024	0.613
Issuance (Retirement) of Debt, Net	-9.5	0.43	-10		0
Foreign Exchange Effects	0.029				0
Net Change in Cash	19.808	-10.15	-7.132	0.079	-51.867
Amortization	1.739
Deferred Taxes	-0.06

	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021
Net income/Starting Line	-8.215	-61.933	-26.475	-8.776	-4.874
Cash From Operating Activities	-7.378	-15.375	-11.949	-4.149	-1.961
Cash From Operating Activities	0.094	0.232	0.132	0.04	0.007
Amortization	0.456	1.739	1.284	0.828	0.411
Deferred Taxes	-0.187	-0.06			0
Non-Cash Items	0.831	47.388	16.165	2.454	2.61
Cash Taxes Paid	0	0.102	0.037	0.031	0.031
Changes in Working Capital	-0.357	-2.741	-3.055	1.305	-0.115
Cash From Investing Activities	0.002	1.855	4.922	5.011	-0.119
Capital Expenditures	-0.007	-0.352	-0.285	-0.196	-0.119
Other Investing Cash Flow Items, Total	0.009	2.207	5.207	5.207	0
Cash From Financing Activities	0	33.299	33.299	36.332	1
Issuance (Retirement) of Debt, Net	0	-9.5	-9.5	-9.5	1
Foreign Exchange Effects	0.021	0.029	0.014	0.012	0.019
Net Change in Cash	-7.355	19.808	26.286	37.206	-1.061
Cash Interest Paid		0.296	0.296	0.296
Issuance (Retirement) of Stock, Net		46.033	46.033	45.832
Financing Cash Flow Items		-3.234	-3.234

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

ReShape Lifesciences Inc. Company profile

About ReShape Lifesciences Inc

ReShape Lifesciences Inc., formerly Obalon Therapeutics, Inc., is a weight-loss solutions company. The Company is focused on offering an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band and associated program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. The ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. The Company's Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kilograms/ square meter.

Financial summary

BRIEF: For the nine months ended 30 September 2021, ReShape Lifesciences Inc revenues increased from $1.5M to $10.5M. Net loss increased from $11M to $26.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $790K to $8.1M (expense), Selling, general and administrative - B increase of 62% to $10.9M (expense).

Industry:

Advanced Medical Equipment & Technology (NEC)

1001 Calle Amanecer
SAN CLEMENTE
CALIFORNIA 92673
US

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023